Cite
HARVARD Citation
Liu, J. et al. (n.d.). 70P A retrospective real-world study of anlotinib plus PD-1 inhibitors in advanced esophageal squamous cell carcinoma (ESCC) previously treated with immune checkpoint inhibitors (ICIs). Immuno-oncology technology. p. . [Online].